Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus

S D Reed; K J Anstrom; A Bakhai; A H Briggs; R M Califf; D J Cohen; M F Drummond; H A Glick; A Gnanasakthy; M A Hlatky; B J O'Brien; F M Torti; A A Tsiatis; A R Willan; D B Mark; K A Schulman

doi:10.1016/j.ahj.2004.11.001

Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus

S D Reed, K J Anstrom, A Bakhai, A H Briggs, R M Califf, D J Cohen, M F Drummond, H A Glick, A Gnanasakthy, M A Hlatky, B J O'Brien, F M Torti, A A Tsiatis, A R Willan, D B Mark, K A Schulman

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Abstract

Demand for economic evaluations in rnultinational clinical trials is increasing, but there is little consensus about how such studies should be conducted and reported. At a workshop in Durham, North Carolina, we sought to identify areas of agreement about how the primary findings of economic evaluations in multinational clinical trials should be generated and presented. In this paper, we propose a framework for classifying multinational economic evaluations according to (a) the sources of an analyst's estimates of resource use and clinical effectiveness and (b) the analyst's method of estimating costs. We review existing studies in the cardiology literature in the context of the proposed framework. We then describe important methodological and practical considerations in conducting multinational economic evaluations and summarize the advantages and disadvantages of each approach. Finally, we describe opportunities for future research. Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies.

Original language	English
Pages (from-to)	434-443
Number of pages	10
Journal	American Heart Journal
Volume	149
Issue number	3
DOIs	https://doi.org/10.1016/j.ahj.2004.11.001
Publication status	Published - Mar 2005

Keywords

SCANDINAVIAN SIMVASTATIN SURVIVAL
ACUTE CORONARY SYNDROMES
CHRONIC HEART-FAILURE
COST-EFFECTIVENESS
HIGH-RISK
INTERNATIONAL DIFFERENCES
SUBGROUP ANALYSIS
RANDOMIZED-TRIAL
EPTIFIBATIDE
RAMIPRIL

Access to Document

10.1016/j.ahj.2004.11.001

Cite this

Reed, S. D., Anstrom, K. J., Bakhai, A., Briggs, A. H., Califf, R. M., Cohen, D. J., Drummond, M. F., Glick, H. A., Gnanasakthy, A., Hlatky, M. A., O'Brien, B. J., Torti, F. M., Tsiatis, A. A., Willan, A. R., Mark, D. B., & Schulman, K. A. (2005). Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. American Heart Journal, 149(3), 434-443. https://doi.org/10.1016/j.ahj.2004.11.001

@article{2bc279d8c9414e78b32ba93a458ec18d,

title = "Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus",

abstract = "Demand for economic evaluations in rnultinational clinical trials is increasing, but there is little consensus about how such studies should be conducted and reported. At a workshop in Durham, North Carolina, we sought to identify areas of agreement about how the primary findings of economic evaluations in multinational clinical trials should be generated and presented. In this paper, we propose a framework for classifying multinational economic evaluations according to (a) the sources of an analyst's estimates of resource use and clinical effectiveness and (b) the analyst's method of estimating costs. We review existing studies in the cardiology literature in the context of the proposed framework. We then describe important methodological and practical considerations in conducting multinational economic evaluations and summarize the advantages and disadvantages of each approach. Finally, we describe opportunities for future research. Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies.",

keywords = "SCANDINAVIAN SIMVASTATIN SURVIVAL, ACUTE CORONARY SYNDROMES, CHRONIC HEART-FAILURE, COST-EFFECTIVENESS, HIGH-RISK, INTERNATIONAL DIFFERENCES, SUBGROUP ANALYSIS, RANDOMIZED-TRIAL, EPTIFIBATIDE, RAMIPRIL",

author = "Reed, {S D} and Anstrom, {K J} and A Bakhai and Briggs, {A H} and Califf, {R M} and Cohen, {D J} and Drummond, {M F} and Glick, {H A} and A Gnanasakthy and Hlatky, {M A} and O'Brien, {B J} and Torti, {F M} and Tsiatis, {A A} and Willan, {A R} and Mark, {D B} and Schulman, {K A}",

year = "2005",

month = mar,

doi = "10.1016/j.ahj.2004.11.001",

language = "English",

volume = "149",

pages = "434--443",

journal = "American Heart Journal",

publisher = "Mosby Inc.",

number = "3",

}

Reed, SD, Anstrom, KJ, Bakhai, A, Briggs, AH, Califf, RM, Cohen, DJ, Drummond, MF, Glick, HA, Gnanasakthy, A, Hlatky, MA, O'Brien, BJ, Torti, FM, Tsiatis, AA, Willan, AR, Mark, DB & Schulman, KA 2005, 'Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus', American Heart Journal, vol. 149, no. 3, pp. 434-443. https://doi.org/10.1016/j.ahj.2004.11.001

TY - JOUR

T1 - Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus

AU - Reed, S D

AU - Anstrom, K J

AU - Bakhai, A

AU - Briggs, A H

AU - Califf, R M

AU - Cohen, D J

AU - Drummond, M F

AU - Glick, H A

AU - Gnanasakthy, A

AU - Hlatky, M A

AU - O'Brien, B J

AU - Torti, F M

AU - Tsiatis, A A

AU - Willan, A R

AU - Mark, D B

AU - Schulman, K A

PY - 2005/3

Y1 - 2005/3

N2 - Demand for economic evaluations in rnultinational clinical trials is increasing, but there is little consensus about how such studies should be conducted and reported. At a workshop in Durham, North Carolina, we sought to identify areas of agreement about how the primary findings of economic evaluations in multinational clinical trials should be generated and presented. In this paper, we propose a framework for classifying multinational economic evaluations according to (a) the sources of an analyst's estimates of resource use and clinical effectiveness and (b) the analyst's method of estimating costs. We review existing studies in the cardiology literature in the context of the proposed framework. We then describe important methodological and practical considerations in conducting multinational economic evaluations and summarize the advantages and disadvantages of each approach. Finally, we describe opportunities for future research. Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies.

AB - Demand for economic evaluations in rnultinational clinical trials is increasing, but there is little consensus about how such studies should be conducted and reported. At a workshop in Durham, North Carolina, we sought to identify areas of agreement about how the primary findings of economic evaluations in multinational clinical trials should be generated and presented. In this paper, we propose a framework for classifying multinational economic evaluations according to (a) the sources of an analyst's estimates of resource use and clinical effectiveness and (b) the analyst's method of estimating costs. We review existing studies in the cardiology literature in the context of the proposed framework. We then describe important methodological and practical considerations in conducting multinational economic evaluations and summarize the advantages and disadvantages of each approach. Finally, we describe opportunities for future research. Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies.

KW - SCANDINAVIAN SIMVASTATIN SURVIVAL

KW - ACUTE CORONARY SYNDROMES

KW - CHRONIC HEART-FAILURE

KW - COST-EFFECTIVENESS

KW - HIGH-RISK

KW - INTERNATIONAL DIFFERENCES

KW - SUBGROUP ANALYSIS

KW - RANDOMIZED-TRIAL

KW - EPTIFIBATIDE

KW - RAMIPRIL

U2 - 10.1016/j.ahj.2004.11.001

DO - 10.1016/j.ahj.2004.11.001

M3 - Article

VL - 149

SP - 434

EP - 443

JO - American Heart Journal

JF - American Heart Journal

IS - 3

ER -